Can Ceragon Networks Ltd (NASDAQ:CRNT) Push Past $2.20?

Ceragon Networks Ltd (NASDAQ:CRNT)

Ceragon Networks Ltd (NASDAQ:CRNT) failed for the fourth time, since mid-August, to close above the $2.20 level. Volume was heavy for the day’s trading as over 1 million shares changed hands on a stock that has an average daily volume of under 360,000.

Ceragon Networks Ltd (NASDAQ:CRNT)

Ceragon Networks Ltd (NASDAQ:CRNT) provides wireless backhaul solutions that enable cellular operators and other wireless service providers to deliver voice, data, and multimedia services globally. Ceragon’s offerings utilize microwave technology to transfer telecommunication traffic between base stations, and the core of the service provider’s network. Their clients include wireless service providers, public safety organizations, government agencies and utility companies

Over two months ago, its FibeAir IP-20 Platform was selected by a Southeast Asia wireless service provider to expand and modernize its nationwide 450MHz low-band high coverage CDMA network to a 4G-LTE network. Even so, the market did not move the shares higher – CDMA shares actually lost ground over the next three days.

CDMA Stock Performance

CDMA has a 52-week high of $4.23 and a 52-week low of $1.88.

Earnings have been erratic for the telecommunications firm. In 2012 the company lost (-$0.64) per share and followed that loss in 2013 with a loss of (-$1.23), and a loss of (-$1.22) in 2014. For 2015, the company posted a per share profit of $0.01 and last year that figure improved to $0.15.

Interestingly, the positive earnings trend comes alongside a decline in reported sales. In 2014 the posted sales figure was $371.1 million, followed by $349.4 million in 2015, and $293.6 million in 2016.

Three investment firms follow Ceragon Networks Ltd (NASDAQ:CRNT). Two rate CRNT shares as a “Hold”, while one rates the shares a “Buy”. Their consensus one-year price target is $2.50.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRNT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Tries to Rebound

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock failed to hold early gains and end the trading session higher for the fourth day in a row. IDRA shares ended at $1.56 after gapping up to open the session at $1.72, which was also the high for the day. Volume was heavy – over three times the 30-day, daily average.

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

IDRA stock had plummeted on October 26, after Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced pricing a share offering at $1.50 – the previous close for IDRA shares was $2.03. The offering was for 33,333,334 shares of its common stock with a 30-day option to for the underwriters to purchase up to an additional 5,000,000 shares of common stock.

J.P. Morgan, Barclays, and Goldman Sachs & Co. LLC are the joint bookrunning managers on the $46.8 million transaction. H.C. Wainwright & Co. is acting as a co-manager on the transaction. Idera Pharmaceuticals Inc (NASDAQ:IDRA) intends to use the net proceeds to advance the development of IMO-2125 in its immuno-oncology program, for working capital, and for other general corporate expenses.

About Idera

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s development program focuses on boosting the immune system to play a more powerful role in fighting cancer, and ultimately increase the number of people who can benefit from immunotherapy. Idera invests in research and development, and works with investigators and partners to address the unmet needs of patients who are suffering from rare, life-threatening diseases.

IDRA Stock Performance

JP Morgan, Wedbush Securities, Piper Jaffray, and Baird all follow Idera Pharmaceuticals Inc (NASDAQ:IDRA) and rate the shares as a “Strong Buy”. The listed consensus one-year price target is $5.75.

Year-to-date ODRA shares are up only 4% – far below the sector’s performance. For the year, IDRA stock is up 0.65% but over the past week, after the company priced the offering at $1.50, shares have lost over 28% of their value.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has posted per share losses since 2012 (-$0.81) but the trend has been favorable and the loss for 2016 was just (-$0.30). Last year the company posted their first significant sales figure of $16.2 million. The downside for investors has been the annual dilution as outstanding shares have increased every year since 2012 when the number of outstanding shares was 27.64 million. But by the end of 2016, and prior to the most recent share offering, over 127 million shares were listed as outstanding.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Hit New Low

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares hit a new 52-week low of $0.90 on a volume figure of 1.2 million shares – almost four times the posted 30-day, daily average. EBIO shares have been on a steady slide since mid-September. In the past month, EBIO shareholders have lost over 37%.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a late-stage, clinical oncology company developing novel product candidates based upon their proprietary targeted protein therapeutics (TPTs) platform. Eleven Biotherapeutics TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule to achieve focused tumor cell killing.

On September 22, 2017 EBIO shares closed at $1.60 – around 60% above today’s closing price. That day Eleven Biotherapeutics Inc (NASDAQ:EBIO) announced that it had completed the manufacturing of all Vicinium for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. Accordingly, Eleven announced ending its large-scale manufacturing activities and redirection of resources towards the completion of its Phase 3 trial and preparing for discussions with the U.S. Food and Drug Administration (FDA) regardingthe submission of a Biologics License Application (BLA) for Vicinium in patients with NMIBC. This change included an impending reduction of headcount.

Eleven Biotherapeutics Performance

In 2012, EBIO shareholders experienced a per share loss of (-$13.91) that was followed in 2013 by a loss of (-$16.19). But in 2014, the per share loss shrank to ($-2.37), then shrank again in 2015. The trend continued and in 2016 the company posted a per share profit of ($0.09).

Sales have been lackluster and registered just $1 million for 2015 but Eleven Biotherapeutics posted sales of $30 million for 2016. Unfortunately, the number of outstanding shares has been increasing and diluting shareholder equity. In 2013 the number of outstanding shares was just 1.35 million. That number was reported at 21.08 million for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Iconix Brand Group Inc (NASDAQ:ICON),

Iconix Brand Group Inc (NASDAQ:ICON) Shares Crash on Wal-Mart Non-renewal

Iconix Brand Group Inc (NASDAQ:ICON)

Iconix Brand Group Inc (NASDAQ:ICON) stock is down over 60% in the last two days after it received notice that Wal-Mart has decided not to distribute the DanskinNow brand beyond January 2019. The market reacted harshly as observers believe the loss of royalty revenues, approximately $15.5 million, may negatively affect Iconix’s ability to service current debt and shrink it lending alternatives.

Iconix Brand Group Inc (NASDAQ:ICON)

Iconix Brand Group Inc (NASDAQ:ICON), headquartered in New York City, is a brand management company that owns, licenses, and markets a portfolio of consumer brands across the women’s, men’s, entertainment, and home industries globally.

John Haugh, CEO of Iconix commented, “Improving the balance sheet, enhancing our liquidity position, and more actively managing our brands continues to be our primary focus.  With our announcement today of Starter at Amazon, we are demonstrating our ability to successfully reposition our brands.  We expect this launch will return Starter to its iconic position of a leading premium athletic brand.  Our team will be pursuing similar strategies as we reposition and build our Mossimo and Danskin brands.  With respect to the balance sheet, we entered into an amendment of our existing credit facility and will be focused on generating funds in the near term to enhance our liquidity position.”

Other Iconix Developments

Today Iconix Brand Group Inc (NASDAQ:ICON) also announced that Starter, an Iconix premium athletic brand, is now available on Amazon Prime.  This new distribution agreement is on the hells of the third quarter 2017 announcement that Starter was no longer exclusive to Walmart.

On October 25, 2017, the United States District Court for the Southern District of New York dismissed the consolidated securities class action brought against Iconix Brand Group Inc (NASDAQ:ICON). In its opinion granting Iconix’s and other defendants’ Motion to Dismiss the matter, the Court provided plaintiffs leave to replead their claims by November 14, 2017.

ICON Stock Performance

ICON stock neared its all-time highs in mid-2014 when the shares were topping out near $45. Since then the shares have slid precipitously and were valued under $10 by early 2016. The recent lows under $2 mark not only 52-week low, but all-time lows. In the last week alone ICON stock has lost almost 70% of its value.

Accordingly, the Relative Strength Index figure is around 12. Experts believe that any value below 20 is usually a trigger for an “oversold” condition, however investors should note that this sell-off follows widely published news of future revenue and earnings losses.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ICON and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Payment Data Systems, Inc. (NASDAQ:PYDS)

Payment Data Systems, Inc. (NASDAQ:PYDS) Post Record Processing Activity

Payment Data Systems, Inc. (NASDAQ:PYDS)

San Antonio, TX-based Payment Data Systems, Inc. (NASDAQ:PYDS) stock rose over 80% after the payment processor announced that its transactions processing volumes for the third quarter of 2017 set an all-time record. PYDS stock closed at $2.59 on a volume figure that was over 150 times the listed daily average. Total dollars processed for the third quarter of 2017 exceeded $704.9 million.

Payment Data Systems, Inc. (NASDAQ:PYDS)

Louis Hoch, President and CEO of Payment Data Systems, stated, “The successful execution of our revenue growth plan is now yielding results. We are pleased at the dramatic growth in the credit card processing segment of our business, and are also pleased to see the growth in our ACH business as compared to second quarter’s downturn. We now have visibility into continued revenue growth throughout the rest of 2017 and for all of 2018.”

Payment Data Systems, Inc. (NASDAQ:PYDS) is an integrated payment solutions provider, and offers a wide range of payment solutions to merchants, billers, banks, service bureaus, and card issuers. The Company operates credit, debit/prepaid and ACH payment processing platforms to deliver convenient, world-class payment solutions and service to their clients.

One year ago, Payment Data Systems, Inc. (NASDAQ:PYDS) hot their 52-week high of $2.65 – $0.06 above today’s losing price. After that high was hit, PYDS shares slid over the next 6-8 months and established a new 52-week low of $1.17. Over the past year the shares have done well – up over 25%. Year-to-date they have performed even better – up 40%.

Analysts have given PYDS stock a consensus one-year price target of $8 even as the shares have been projected to post negative earnings of 20%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PYDS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Drops After Pricing Offering

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares fell 14.7% after announcing the pricing of a previously announced public offering of 9 million shares on the Tel-Aviv Stock Exchange. The developer of placenta-based cell therapy products has priced the offering at $1.67 a share and expects gross proceeds of $15.1 million.

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

PSTI Investors Reaction

The accepted orders in the aggregate amount of $15.1 million after the offering became over-subscribed. The minimum share price consequently increased from $1.61 to $1.67 a share. The offering should close on or about December 31, 2017.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) plans to use net proceeds from the offering for research and product development. Part of the funds will also to be used to finance clinical trial activities, working capital, and for other general corporate purposes.

Investors reacted to the public offering pricing by pushing the stock lower. A point of concern is that the public offering was priced at a discount and that it could lead to further dilution of the stock. However, the stock continues to trade in an uptrend. The stock is up by more than 10% for the year.

PLX-R18 Development

The pricing of the public offering follows the Israel’s Ministry of Health approval of the company’s Phase 1 study of drug candidate PLX-R18. Pluristem Therapeutics Inc. (NASDAQ:PSTI) is investigating the drug candidate for the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation HCT. The U.S. Food and Drug Administration (FDA) has also approved the trial. In the United States, Pluristem is to recruit up to 30 patients for the trial.

“We’re very pleased with the Israeli Ministry of Health’s vote of confidence in our innovative therapies and efforts to provide treatments for a range of hematopoietic conditions, including insufficient recovery from hematopoietic stem cell transplants,” stated Zami Aberman, Pluristem Co-CEO, and Chairman

In addition, PLX-R18 is in late-stage development as a treatment for acute radiation syndrome (ARS). The cell therapy is designed to treat bone marrow that is unable to produce enough blood cells due to ARS. Pluristem Therapeutics Inc. (NASDAQ:PSTI) holds several patents that cover PLX-r18 for the treatment of impaired hematopoietic systems in case of a bone marrow transplant.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

MagneGas Corporation (NASDAQ:MNGA)

MagneGas Corporation (NASDAQ:MNGA) Projects Revenue Growth

MagneGas Corporation (NASDAQ:MNGA) Projects Revenue Growth

MagneGas Corporation (NASDAQ:MNGA) shares traded higher after the clean technology company said it expects its full-year revenues to increase by 120%. The stock gained 2.2% to end Monday’s trading session at $0.435 a share.

MagneGas Corporation (NASDAQ:MNGA) Projects Revenue Growth

Revenue Growth

Monday’s rally did not have a big impact on the stock’s direction of trade. MagneGas Corporation (NASDAQ:MNGA) stock is down by more than 80% for the year.

For the full year, the company expects revenues of $7.5 million, up from $3.4 million reported last year. The expected growth follows the execution of an ambitious growth strategy over the past year, which Chief Financial Officer, Scott Mahoney, says has allowed the company to focus on sales.

MagneGas Corporation (NASDAQ:MNGA) has successfully expanded its distribution network by expanding relationships across the eastern part of the U.S. in addition to pursuing sales opportunities in Italy and Germany.

“The Company made a strategic decision a year ago to focus on immediate revenue generation, improving cash flows and profitability. I am pleased to report that we have turned the corner, and we are on pace to generate more revenues in the fourth quarter of 2017 than we have in any full fiscal year in our corporate history,” said Ermanno Santilli, CEO of MagneGas.

The ambitious growth strategy has allowed MagneGas Corporation (NASDAQ:MNGA) to record a material increases in operating cash flows.

4th Generation Gasification System

Separately, MagneGas Corporation (NASDAQ:MNGA) has completed the design process of a revolutionary 4th generation gasification system. Development of the new system is expected to put the company ahead of the competition.

The 4th generation gasification system will reduce total production costs by at least 50% in addition to a 75% reduction in power consumption per cubic foot. MagneGas hopes the new gasification system will gain significant market share.

“This new system should significantly reduce the cost of MagneGas2® production. It also has the potential to open lucrative markets in the gasification of solids and solid wastes such as coal and plastics,” said Mr. Santilli.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNGA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Bounces off Lows

Immune Design Corp (NASDAQ:IMDZ)

Shares of Immune Design Corp (NASDAQ:IMDZ) gained 12.2% ahead of their much-awaited financial results for the third quarter, ended September 30, 2017. The clinical stage immunotherapy company will release the results on November 1, 2017, after the close of the U.S. markets.

Immune Design Corp (NASDAQ:IMDZ)

Earnings Expectations

Investor confidence in the stock has taken a hit this month as seen by the stock shedding more than 50% in its market value. The stock has come under pressure following the pricing of an underwritten public offering of 19.5 million shares at a price of $4.10 a share. Investors pushed the stock lower after the company offered the shares at a discount to the market price.

Last quarter, the immunotherapy company reported a positive earnings surprise of 16.92% outpacing the consensus estimates of average earnings beat of 12.94%. A similar performance with Q3 financial results could result in the stock bouncing back from current trading levels.

Increased implied volatility on Immune Design Corp (NASDAQ:IMDZ) November options is already fuelling suggestions of a potential big move in either direction. Analysts at Zack’s research currently rate the stock as a ‘hold’.

Immune Design Pipeline

Progress on the company’s pipeline candidates should have an impact on the stock’s direction of trade going forward. The company’s lead candidate drugs are CMB305 for the treatment of solid tumor and G100 for the treatment of merkel cell carcinoma.

Immune Design is evaluating CMB305 both as a monotherapy and in combination with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Tecentriq. G100 is being developed on the GLAAS platform in collaboration with Merck for the treatment of patients with non-Hodgkin’s lymphoma (NHL).

The European Medicine Agency has granted G100 Orphan Drug Designation for the treatment of NHL. The designation is expected to accelerate its development while also guaranteeing market exclusivity for up to 10 years.

Immune Design Corp (NASDAQ:IMDZ) has the financial power to accelerate the development of the two candidate drugs given the pricing of the $80 million public offering.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Helios and Matheson Analytics Inc. (NASDAQ:HMNY)

Helios and Matheson Analytics Inc. (NASDAQ:HMNY) Down on Subscriber Math

Helios and Matheson Analytics Inc. (NASDAQ:HMNY)

Shares of Helios and Matheson Analytics Inc. (NASDAQ:HMNY) continued their long slide even as the company announced massive subscriber growth in its wholly owned subsidiary, MoviePass. Shares of the company fell 15.92% in Monday’s trading session to end the day at $9.03 a share.

Helios and Matheson Analytics Inc. (NASDAQ:HMNY)

HMNY Stock Performance

Monday’s sell-off capped yet another poor showing in the market on the back of positive news. Over the past month, the stock has shed more than 60% in the market, as the downward spiral shows no signs of slowing down.

Helios and Matheson Analytics Inc. (NASDAQ:HMNY) shares experienced a breathtaking spike in revenues after MoviePass announced an 80% reduction in its monthly subscription fee. The reduction led to an increase in the number of subscribers from 20,000 to 600,000 in less than two months.

Investor confidence on the stock has since taken a hit on concerns that MoviePass’ business model could drain a lot of capital in the near term. The Helios and Matheson Analytics subsidiary lets members watch one standard movie screening per day at any theater that accepts its debit card.

Profits Concerns

The math behind the $9.95 a month plan continues to arouse concerns as the company stands to lose money should subscribers watch more than one movie a month.

Confusion over how Helios and Matheson Analytics Inc. (NASDAQ:HMNY) will be able to generate profit under the current business model is another headwind that continues to plague the stock. A few weeks ago MoviePass CEO Mitch Lowe, said they will be able to break even on current subscribers buying at least one movie ticket. Fast forward, the tune has changed, and the executive insists that users may have to buy multiple tickets.

In what many observers believe is an attempt to prevent a further slide of the stock, Helios and Matheson Analytics Inc. (NASDAQ:HMNY) CEO has hinted at the possibility of generating some value from subscriber data.

“When you apply computer science and machine learning to an industry that we believe has lacked significant innovation, useful patterns start to emerge,” Helios and Matheson CEO Ted Farnsworth says in last week’s press release. “More subscribers mean more data.”

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $HMNY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) Continues to Jet Higher

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) has recorded a new inter-day 52-week high, $4.10, on volume that is five times the listed daily average. While the broad market indexes are all pulling back, LPTH shares are on track to post a 27% gain in just the past week.

LightPath Technologies, Inc. (NASDAQ:LPTH)

Orlando, FL-based LightPath Technologies, Inc. (NASDAQ:LPTH) is a vertically integrated provider of optics, photonics and infrared solutions for the global industrial, defense, telecommunications, testing and measurement, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and gradient index GRADIUM® lenses. LightPath also offers custom optical assemblies, including full engineering design support.

LPTH Stock Performance

Shareholders of LightPath Technologies, Inc. (NASDAQ:LPTH) have fared well in 2017. Year-to-date, LPTH shares are up over 143%. This high level of performance is also reflected in the stock’s Relative Strength Index (RSI) figure of 86. Many investors and traders believe a figure over 70 reflects an “overbought” condition in a security, however LPTH shares have been over 70 for at least a month and the market seems to believe that higher prices are justified by recent earnings which are up 300% over the previous year. Financial analysts are expecting earnings growth for next year to be around 22%.

In 2015, LightPath posted a per share loss of ($0.05) but followed that in 2016 with a profit of ($0.09) per share, and profit of ($0.39) in FY2017. Sales have followed a similar path. For 2014, LightPath Technologies, Inc. (NASDAQ:LPTH) reported sales of $11.8 million. That number increased every year and in FY2017 the number was $28.4 million.

Two investment firms follow LightPath Technologies, Inc. (NASDAQ:LPTH). Both rate the shares as a “Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LPTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.